Using the same assays as for the original Project MinE variants, we identified patient-associated Answer ALS variant, R267W SARM1, as an additional strong GoF, with robust NAD+-consuming activity in transfected HEK 293T cells combined with low expression (Figure 4A and B) and a constitutively high, non-inducible NADase activity equivalent to that of the strongest Project MinE GoF variants (Figure 4C,E). Here, SARM1 is linked to amyotrophic lateral sclerosis.